These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1241 related articles for article (PubMed ID: 25687024)
1. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis. Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children. Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey. Gunay M; Sukgen EA; Celik G; Kocluk Y Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302 [TBL] [Abstract][Full Text] [Related]
4. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. Isaac M; Mireskandari K; Tehrani N J AAPOS; 2015 Apr; 19(2):140-4. PubMed ID: 25892041 [TBL] [Abstract][Full Text] [Related]
5. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA; JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848 [TBL] [Abstract][Full Text] [Related]
6. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results]. Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695 [TBL] [Abstract][Full Text] [Related]
7. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy. Kuo HK; Sun IT; Chung MY; Chen YH Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192 [TBL] [Abstract][Full Text] [Related]
9. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Mueller B; Salchow DJ; Waffenschmidt E; Joussen AM; Schmalisch G; Czernik C; Bührer C; Schunk KU; Girschick HJ; Winterhalter S Br J Ophthalmol; 2017 Mar; 101(3):365-370. PubMed ID: 27301450 [TBL] [Abstract][Full Text] [Related]
10. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal injection of bevacizumab for retinopathy of prematurity. Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819 [TBL] [Abstract][Full Text] [Related]
12. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison. Han J; Kim SE; Lee SC; Lee CS Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262 [TBL] [Abstract][Full Text] [Related]
13. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY. Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460 [TBL] [Abstract][Full Text] [Related]
14. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Kim J; Kim SJ; Chang YS; Park WS Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184 [TBL] [Abstract][Full Text] [Related]
15. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan. Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589 [TBL] [Abstract][Full Text] [Related]
16. Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP. Anand N; Blair MP; Greenwald MJ; Rodriguez SH J AAPOS; 2019 Apr; 23(2):88.e1-88.e6. PubMed ID: 30797978 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity. Ekinci DY; Çelik K J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042 [TBL] [Abstract][Full Text] [Related]
19. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor. Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G; Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554 [TBL] [Abstract][Full Text] [Related]
20. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity. Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]